HighTower Advisors
OACC

HighTower Advisors’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

HighTower Advisors’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-510,836
Closed -$5.4M – 4043
2026
Q1 		$5.4M Sell
510,836
-116,193
-19% -$1.24M 0.01% 1163
2025
Q4 		$6.63M Sell
627,029
-30,599
-5% -$324K 0.01% 1039
2025
Q3 		$6.91M Sell
657,628
-29,065
-4% -$304K 0.01% 1007
2025
Q2 		$7.18M Buy
686,693
+549,704
+401% +$5.7M 0.01% 941
2025
Q1 		$1.4M Buy
+136,989
New +$1.37M ﹤0.01% 1740

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.37B AUM 26.91% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BGGS
Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HighTower Advisors's OACC Position: Q2 2026 in Review

HighTower Advisors sold out of Oaktree Acquisition Corp III Life Sciences (OACC) in Q2 2026, closing a stake of 510,836 shares — an estimated $5.4M sold.

HighTower Advisors first reported a position in OACC in Q1 2025 and held it in 5 quarters. The position peaked at $7.18M in Q2 2025. 51 funds tracked by Wall St. Rank hold OACC as of Q2 2026.

  • HighTower Advisors reported no remaining Oaktree Acquisition Corp III Life Sciences position as of Q2 2026 after selling out during the quarter.
  • HighTower Advisors sold 510,836 Oaktree Acquisition Corp III Life Sciences shares in Q2 2026, an estimated $5.4M.
  • HighTower Advisors first reported a position in Oaktree Acquisition Corp III Life Sciences in Q1 2025 and held it in 5 quarters.
  • HighTower Advisors's Oaktree Acquisition Corp III Life Sciences position peaked at $7.18M in Q2 2025.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.